Sanofi, Novo back a small biotech that's neck and neck with Pfizer to develop a Group B streptococcus vaccine
Per Fischer is used to going into meetings with Big Pharma — usually surrounded by 20 to 30 people on their vaccine development teams — alone.
For the past 9 years as the CEO of MinervaX, Fischer has been the closest person to a full-time employee, working four days a week with 5 part-time consultants on a shot that can protect pregnant women and their babies from Group B streptococcus. With €27 million in seed funding, grants and small investments, the virtual biotech has turned an academic project out of Sweden’s Lund University into a Phase II program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
